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Metabolic rescue in pluripotent cells from
patients with mtDNA disease
Hong Ma1,2, Clifford D. L. Folmes3, JunWu4, Robert Morey5, Sergio Mora-Castilla5, Alejandro Ocampo4, Li Ma4, Joanna Poulton6,
Xinjian Wang7, Riffat Ahmed1,2, Eunju Kang1,2, Yeonmi Lee1,2, Tomonari Hayama1,2, Ying Li1,2, Crystal Van Dyken1,2,
Nuria Marti Gutierrez1,2, Rebecca Tippner-Hedges1,2, Amy Koski1,2, Nargiz Mitalipov1,2, Paula Amato8, Don P. Wolf2,
Taosheng Huang7, Andre Terzic3, Louise C. Laurent5, Juan Carlos Izpisua Belmonte4 & Shoukhrat Mitalipov1,2
Mitochondria have amajor role in energy production via oxidative
phosphorylation1, which is dependent on the expression of critical
genes encoded by mitochondrial (mt)DNA. Mutations in mtDNA
can cause fatal or severely debilitating disorders with limited treat-
ment options2. Clinical manifestations vary based on mutation
type and heteroplasmy (that is, the relative levels of mutant and
wild-type mtDNA within each cell)3,4. Here we generated genetic-
ally corrected pluripotent stem cells (PSCs) from patients with
mtDNA disease. Multiple induced pluripotent stem (iPS) cell lines
were derived frompatients with common heteroplasmicmutations
including 3243A.G, causing mitochondrial encephalomyopathy
and stroke-like episodes (MELAS)5, and 8993T.G and 13513G.A,
implicated in Leigh syndrome. Isogenic MELAS and Leigh syn-
drome iPS cell lines were generated containing exclusively wild-
type or mutant mtDNA through spontaneous segregation of
heteroplasmic mtDNA in proliferating fibroblasts. Furthermore,
somatic cell nuclear transfer (SCNT) enabled replacement of
mutant mtDNA from homoplasmic 8993T.G fibroblasts to gen-
erate corrected Leigh-NT1 PSCs. Although Leigh-NT1 PSCs con-
tained donor oocyte wild-type mtDNA (human haplotype D4a)
that differed from Leigh syndrome patient haplotype (F1a) at a
total of 47 nucleotide sites, Leigh-NT1 cells displayed transcrip-
tomic profiles similar to those in embryo-derived PSCs carrying
wild-type mtDNA, indicative of normal nuclear-to-mitochondrial
interactions. Moreover, genetically rescued patient PSCs displayed
normal metabolic function compared to impaired oxygen con-
sumption and ATP production observed in mutant cells. We con-
clude that both reprogramming approaches offer complementary
strategies for derivation of PSCs containing exclusively wild-type
mtDNA, through spontaneous segregation of heteroplasmic
mtDNA in individual iPS cell lines or mitochondrial replacement
by SCNT in homoplasmic mtDNA-based disease.
Maternally inherited mtDNA encodes 13 proteins critical for
oxidative phosphorylation, while the remaining protein subunits are
encoded by nuclear DNA. Therefore, mitochondrial biogenesis
requires coordinated interaction of protein subunits encoded by both
genomes2. Mutations in mtDNA occur at a higher rate than in nuclear
DNA, resulting in life-threatening conditions3,6.
We have described a strategy to prevent transmission of mtDNA
mutations to children involving mitochondrial replacement7. To
explore the feasibility of generating genetically corrected autologous
PSCs, herein, we focus on three of the most common pathogenic
mtDNA mutations. Skin samples were donated by a MELAS patient
carrying a 3243A.G heteroplasmic mutation in tRNALeu (MT-TL1)8
and by Leigh syndrome patients carrying heteroplasmic or homoplas-
mic 8993T.G mutations affecting the ATPase 6 gene (MT-ATP6)3,
andheteroplasmic 13513G.Amutation in theMT-ND5 gene9. Apanel
of ten iPS cell lines from each mutation type was generated and quant-
itative mtDNA mutation analysis was carried out using amplification
refractory mutation system-quantitative polymerase chain reaction
(ARMs-qPCR), with a detection threshold of 0.5%. In MELAS iPS cell
lines, the mutation was undetectable in five lines and varied from 33%
to 100% in the remaining five lines, compared to 29% heteroplasmy in
parental fibroblasts (Table 1 andExtendedData Fig. 1a). In iPS cell lines
from the heteroplasmic 8993T.G mutation, the mutation was unde-
tectable in one line and ranged from 29% to 87% in the remaining lines,
compared to 52% heteroplasmy in parental fibroblasts (Table 1 and
ExtendedData Fig. 1b).Mutation segregation in individual iPS cell lines
from 13513G.A fibroblasts also ranged from 0% to 100%, compared
to 84%heteroplasmy in fibroblasts (Table 1 andExtendedData Fig. 1c).
Previous studies suggested that segregation of heteroplasmicmtDNA is
specific to iPS cells and may occur during or after reprogramming10,11.
To explore mechanisms, parental fibroblasts carrying 3243A.G and
13513G.A mutations were subcloned and mutation loads in indi-
vidual clones were analysed. Among ten randomly selected MELAS
samples, five were homoplasmic containing either wild type (A) or
mutant (G) at the 3243 position. The remaining five contained varying
heteroplasmy levels similar to iPS cells (Table 1 and Extended Data
Fig. 1d).Variable heteroplasmy levelswere also observed in 13513G.A
fibroblasts including homoplasmic mutant and wild-type clones
(Table 1). Thus, segregation of heteroplasmic mtDNA mutations
occurs in skin fibroblasts and may reflect a common phenomenon12.
Isogeneic MELAS iPS cell lines carrying wild-type or mutant
mtDNA maintained typical PSC morphology and formed teratomas
containing cells and tissues from all three germ layers (Extended Data
Fig. 2a, b). We next carried out whole mtDNA sequencing using the
Illumina MiSeq platform and confirmed the 3243A.G mutation in
parental MELAS-fib (46.8%), MELAS-iPS1 and MELAS-iPS3 (100%)
cells while MELAS-iPS2 was homoplasmic for the wild-type allele
(Supplementary Table 1). MELAS-fib also carried four additional het-
eroplasmic mutations with one variant carried to MELAS-iPS1 and
MELAS-iPS2 (Supplementary Table 1).
The 3243A.G mutation perturbs tRNALeu function and impairs
mitochondrial protein synthesis aswell as respiratory complex activity,
with the homoplasmic mutation leading to prenatal lethality in
humans13. Oxygen consumption rate (OCR) was employed as an indi-
cator of mitochondrial respiration and energy production. Mutant
MELAS-iPS1 and MELAS-iPS3 exhibited significantly lower OCR
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(P, 0.05) when compared to the wild-type MELAS-iPS2 (Fig. 1a).
Fibroblasts differentiated from MELAS-iPS1 and parental MELAS-
fib also displayed low levels of mitochondrial function. In contrast,
these respiratory defects were absent in MELAS-iPS2-derived fibro-
blasts. In general, mitochondrial respiration correlated with the het-
eroplasmy levels in cells (Fig. 1b and Table 1). The greater reliance on
oxidative metabolism in wild-typeMELAS-iPS2 was confirmed by the
elevated OCR to ECAR (extracellular acidification rate) ratio, which
provides a measure for the relative contribution of oxidative metabol-
ism versus glycolysis (ExtendedData Fig. 3a).MutantMELAS iPS cells
and their derivatives displayed significantly decreased OCR/ECAR
ratios, indicating a greater reliance on glycolysis (Extended Data
Fig. 3a, b). We next differentiated MELAS iPS cells into neuronal
progenitor cells (NPCs, Extended Data Fig. 3c, d)14,15. Diminished
metabolic profiles in mutant NPCs recapitulated those observed in
undifferentiated iPS cells (Extended Data Fig. 3e). Cardiomyocyte
differentiation15 of mutant MELAS iPS cells was severely compro-
mised due to massive cell death.
As expected, all iPS cell lines from homoplasmic 8993T.G fibro-
blasts carried mutant mtDNA (Extended Data Fig. 1e and Extended
Table 1 | Distribution of mtDNA variants in fibroblast and iPS clones derived from patients with heteroplasmic mutations
iPS clones Fibroblast clones
3243
A.G
Mutant G (%) 8993
T.G
Mutant G (%) 13513
G.A
Mutant A (%) 3243
A.G
Mutant G (%) 13513
G.A
Mutant A (%)
Parental
fibroblasts
29 Parental
fibroblasts
52 Parental
fibroblasts
84 Parental
fibroblasts
29 Parental
fibroblasts
84
iPS1 100 iPS1 62 iPS1 100 fib1 100 fib1 0
iPS2 0 iPS2 72 iPS2 2 fib2 100 fib2 68
iPS3 100 iPS3 32 iPS3 4 fib3 0 fib3 24
iPS4 0 iPS4 52 iPS4 0 fib4 93 fib4 64
iPS5 0 iPS5 29 iPS5 80 fib5 8 fib5 58
iPS6 33 iPS6 66 iPS6 11 fib6 21 fib6 48
iPS7 0 iPS7 87 iPS7 19 fib7 3 fib7 69
iPS8 78 iPS8 72 iPS8 32 fib8 97 fib8 70
iPS9 88 iPS9 46 iPS9 100 fib9 100 fib9 63
iPS10 0 iPS10 0 iPS10 72 fib10 0 fib10 100
Differentiated fibroblastsUndifferentiated pluripotent stem cellsa b
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Figure 1 | Mitochondrial respiratory function in MELAS samples.
a, Oxygen consumption rate (OCR) in undifferentiatedMELAS-iPS1,MELAS-
iPS2 and MELAS-iPS3 cells (n5 9 per cell line, biological replicates) in
response to 0.5mgml21 oligomyocin, 1mM fluorocarbonyl cyanide phenyl-
hydrazone (FCCP), 0.5mM rotenone and 1mMantimycin. Wild-type MELAS-
iPS2 displayed higher levels of oxygen consumptionwhen compared tomutant
MELAS-iPS1 and MELAS-iPS3. b, OCR in MELAS-iPS1 and MELAS-iPS2
derived fibroblasts and parental MELAS-fib (n5 10 per cell line, biological
replicates). Error bars are mean 6 s.e.m. and OCR data are representative of
at least 2–3 independent experiments. Significance established with one-way
analysis of variance (ANOVA) with Tukey’s multiple comparison test.
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Data Table 1). Therefore, we pursued mitochondrial replacement by
SCNT with wild-type oocyte mitochondria. Following our reported
protocol, two stable nuclear transfer–embryonic stem cell lines were
established (Leigh-NT1 andLeigh-NT2)16. Genotyping confirmed that
both lines contained predominantly oocyte wild-type mtDNA
(Extended Data Fig. 1f) with limited low mutated mtDNA carryover
(,1%) at passage 5 that became undetectable upon extended propaga-
tion (Extended Data Table 2).
Cytogenetic G-banding revealed that Leigh-iPS1 and Leigh-NT1
retained normal diploid karyotypes with no detectable numerical or
structural chromosomal abnormalities (Extended Data Fig. 2c).
However, Leigh-NT2 showed a XXXY tetraploid karyotype
(Extended Data Fig. 2c). Fingerprinting by short tandem repeat ana-
lysis (STR) also revealed that Leigh-NT2 contained both oocyte and
Leigh-fib alleles (Extended Data Table 3), consistent with failed enuc-
leation. STR profiles for Leigh-NT1 and Leigh-iPS1 were identical to
Leigh-fib (Extended Data Table 3). Both Leigh-iPS1 and Leigh-NT1
lines maintained typical PSC morphology, expressed pluripotency
markers7 and formed teratomas containing cells and tissues from all
three germ layers (Extended Data Fig. 2d, e).
Table 2 | Summary of 47 SNPs found in the mtDNA of Leigh-fib and Leigh-NT1 lines
Nucleotide position Leigh-NT1 Leigh-fib Locus Effects Nucleotide position Leigh-NT1 Leigh-fib Locus Effects
152 C T Control region 10400 T C MT-ND3 Syn
248 A Deletion Control region – 10410 C T MT-TR –
489 C T Control region – 10609 T C MT-ND4L Non-syn
3010 A G MT-RNR2 – 10873 C T MT-ND4 Syn
3206 T C MT-RNR2 – 12406 G A MT-ND5 Non-syn
3970 C T MT-ND1 Syn 12418 Deletion A MT-ND5 Frame shift
4086 C T MT-ND1 Syn 12705 T C MT-ND5 Syn
4216 T C MT-ND1 Non-syn 12882 C T MT-ND5 Syn
4883 T C MT-ND2 Syn 13759 G A MT-ND5 Non-syn
5178 A C MT-ND2 Non-syn 13928 G C MT-ND5 Non-syn
6392 T C MT-CO1 Syn 14668 T C MT-ND6 Syn
6527 A G MT-CO1 Syn 14783 C T MT-CYB Syn
6962 G A MT-CO1 Syn 14979 C T MT-CYB Non-syn
7775 A G MT-CO2 Non-syn 15043 A G MT-CYB Syn
8414 T C MT-ATP8 Non-syn 15301 A G MT-CYB Syn
8473 C T MT-ATP8 Syn 15676 T C MT-CYB Syn
8507 A G MT-ATP8 Non-syn 16148 C T Control region –
8701 G A MT-ATP6 Non-syn 16162 A G Control region –
8993 T G MT-ATP6 Non-syn 16172 T C Control region –
9053 G A MT-ATP6 Non-syn 16223 T C Control region –
9540 C T MT-CO3 Syn 16244 G A Control region –
9548 G A MT-CO3 Syn 16304 T C Control region –
10310 G A MT-ND3 Syn 16362 C T Control region –
10398 G A MT-ND3 Non-syn
Syn, synonymous; non-syn, non-synonymous.
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Figure 2 | Restoration ofmitochondrial respiratory function in Leigh-NT1.
a, OCR in Leigh-NT1, Leigh-iPS1 and Leigh-iPS2 derived fibroblasts, parental
and oocyte donor fibroblasts (n5 9, 8, 10, 9 and 8 per cell line, respectively,
biological replicates). b, OCR in Leigh-NT1and Leigh-iPS1 derived skeletal
muscle cells (n5 6 biological replicates per cell line). c, mtDNA haplotype
distances for oocyte and somatic cell donors based on mitochondrial
phylogenetic tree from PhyloTree (http://phylotree.org/tree/main.htm)27.
Asterisks indicate subgroups for mtDNA haplotypes. Error bars are
mean6 s.e.m. and OCR data are representative of at least 2–3 independent
experiments. Significance established using Kruskal–Wallis with Dunn’s
multiple comparison test or one-way ANOVA with Tukey’s multiple
comparison test (maximum respiration in a) and Student’s t-test in b.
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Whole mtDNA sequencing confirmed the presence of homoplas-
mic 8993T.G mutation in Leigh-fib and Leigh-iPS1 and also iden-
tified a second homoplasmic 4216T.C mutation in the MT-ND1
gene (Extended Data Fig. 1f and Supplementary Table 2). This non-
synonymous mutation has been previously associated with Leber’s
hereditary optic neuropathy15. Leigh-NT1 mtDNA sequence differed
fromLeigh-fib at 47 nucleotide positions. In addition to the pathogenic
8993T.G and 4216T.C mutations, differences included 10 single
nucleotide polymorphisms (SNPs) in the D-loop region, 2 in the 16S
rRNA gene, 1 in the tRNA-R gene and 34 in protein genes (Table 2).
We also detected two heteroplasmic variants in Leigh-NT1, four in
Leigh-fib and three in Leigh-iPS1 (Supplementary Table 2). Clinical
symptoms associated with these variants have not been reported.
We measured metabolic function in fibroblasts differentiated
from Leigh-NT1, Leigh-iPS1 and Leigh-iPS2 and compared them to
parental Leigh-fib and healthy skin fibroblasts from the oocyte donor.
As expected, the homoplasmic 8993T.G mutation resulted in low
mitochondrial oxidative capacity. In contrast, these respiration defects
were absent in fibroblasts differentiated from Leigh-NT1 (Fig. 2a).
Leigh-NT1 also displayed a metabolic profile and OCR/ECAR ratios
similar to oocyte donor fibroblasts (Fig. 2a and ExtendedData Fig. 4a).
We observed varying levels of oxidative reserve for Leigh-iPS1
and Leigh-iPS2 compared to parental Leigh-fib (Fig. 2a), reflecting
inherent variability within differentiated fibroblast populations.
Both Leigh-NT1 and Leigh-iPS1 effectively generated skeletal muscle
cells17 (Extended Data Fig. 4b), with Leigh-iPS1 skeletal muscle cells
displaying significantly lower ATP turnover (P, 0.05) (Fig. 2b).
Extensive cell death was observed in Leigh-iPS1 during directed car-
diomyocyte differentiation (Extended Data Fig. 4c). These results
demonstrate complete functional rescue of mitochondrial activity in
Leigh-NT1 through restoration of the wild-type mtDNA.
Evolution of mtDNAhas resulted in a series of neutral polymorphic
variants within the human population often associated with regional
migration and adaptation to climate18. The largest difference between
distant human mtDNA haplotypes has been estimated at 95 SNPs19.
In the present study, phylogenetic analysis assigned oocyte and
Leigh-NT1 mtDNA to the D4a haplotype while the Leigh-iPS1 and
Leigh-fib mtDNA haplotype was F1a (Supplementary Table 2).
D4a is a descendant from the M while F1a comes from the N
macro-haplo-group per the human mtDNA mutation tree (Fig. 2c).
Safety evaluations of mitochondrial replacement therapy suggest pos-
sible harmful secondary outcomes reflecting nuclear–mitochondrial
incompatibility20,21. Despite ‘unmatched’ donor mtDNA, Leigh-NT1
demonstrated lineage-specific differentiation and restoration of meta-
bolic activity, implying normal nuclear–mitochondrial interaction.
We further investigated a hESO-NT1 derived by SCNT from healthy
fetal fibroblasts (human dermal fibroblast (HDF)) and IVF-derived
hESO-8 carrying identical mtDNA16. hESO-NT1 mtDNA differed
from HDF at 12 nucleotide positions (Fig. 2c and Supplementary
Table 3). Metabolic profiles in NPCs and cardiomyocytes differen-
tiated from hESO-NT1 and hESO-8 displayed similar metabolic pro-
files (Extended Data Fig. 5a–e). Next, we asked whether the 3243A.G
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Figure 3 | Global gene expression analysis by
RNA-seq. a, Heat map displaying 345 genes
that are differentially expressed (adjusted P value
,0.05) between wild-type PSCs (biological
duplicates of 3 independent cell lines) versusmutant
PSCs (biological duplicates of 5 independent cell
lines). b, Functional enrichment analysis of genes
displayed in the heat map that are known to be
correlated with a response to oxidative stress.
c, Functional enrichment analysis of genes
displayed in the heat map that are known to be
correlated with a response to hypoxia. Bar graphs
are mean6 s.e.m., using all samples described in a.
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and 8993T.G mutations induced detectable changes in global gene
expression and compared transcriptomes by RNA-seq for undiffer-
entiated and differentiated PSCs. Undifferentiated PSCs containing
wild-type ormutantmtDNA showed 154 differentially expressed tran-
scripts (adjusted P value,0.05 ). This small number of differences is
consistent with the predominantly glycolytic metabolism of pluripo-
tent stem cells, which protects them from the deleterious effects of
mtDNA mutations22. Global gene expression analysis of fibroblasts
differentiated from isogenic MELAS lines identified 1,118 differenti-
ally expressed genes in mutant and wild-type cells (Extended Data
Fig. 6a), whereas 2,950 genes were differentially expressed in fibro-
blasts differentiated from mutant Leigh-iPS1, Leigh-iPS2 and Leigh-
iPS3 compared to the wild-type Leigh-NT1 cells (Extended Data
Fig. 6b). Hierarchical clustering using a multiple bootstrap resampling
algorithm showed that the Leigh-NT1 fibroblasts were similar to
hESO-NT1, hESO-NT2, hESO-7 and hESO-8 fibroblasts (Extended
Data Fig. 6c). These findings further support the notion that oocyte
mtDNA in Leigh-NT1 interacts normally with nuclear DNA as long as
the mtDNA sequence differences are neutral.
Next, we asked whether any of the differentially expressed genes
were common to both 3243A.Gand 8993T.Gmutations, and found
345 genes that were shared, 96% of which were overexpressed in
the mutant cells (Fig. 3a). Functional enrichment analysis identified
genes associated with a response to hypoxia and oxidative stress23,24
(Fig. 3b, c; P value ,0.001). However, we did not observe an enrich-
ment of genes associated with metabolism, stress response, epigenetic
regulation, and cell signalling, which was reported in a recent MELAS
study13 (Extended Data Fig. 6d).
Finally, we addressed whether the 3243A.G and 8993T.G
mutations specifically impact gene expression of mtDNA-encoded
transcripts25. We found that transcripts expressed from mtDNA
accounted for approximately 20% of the total cellular transcriptome,
with similar expression levels across different mutations (Extended
Data Fig. 7; adjusted P value .0.05).
We demonstrate complementary strategies for generating genetic-
ally and functionally corrected PSCs for patients with mtDNA disease.
For the most common mtDNA syndromes caused by heteroplasmic
mutations, generation ofmultiple iPS cell lines allows recovery of clones
with exclusively wild-type mtDNA due to spontaneous segregation of
heteroplasmic mtDNA. SCNT enables correction of homoplasmic
mutations through replacement with donor mtDNA, and generation
of PSCs with transcriptional and epigenetic profiles similar to embryo-
derived embryonic stem cells26. Recovery of metabolic function despite
haplotype differences between patient and donormtDNA suggests that
normal nuclear-to-mitochondrial interactions are highly conserved
within species. Generation of genetically corrected PSCs from patients
with mtDNA disease enables the transition from palliative care to
therapeutic interventions based on regenerative medicine.
Online ContentMethods, along with any additional Extended Data display items
andSourceData, are available in theonline versionof thepaper; referencesunique
to these sections appear only in the online paper.
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METHODS
The study protocols and informed consent for human subjects were approved
by the OHSU Embryonic Stem Cell Research Oversight Committee and the
Institutional Review Board. No statistical methods were used to predetermine
sample size.
SCNT and iPS cell derivation and culture. Fibroblasts were acquired from
Coriell Cell Repositories or donated by patients directly for our study.
Fibroblasts were cultured in DMEM F12 medium supplemented with 10%
fetal bovine serum (HyClone) and 50mM uridine. SCNT procedures were per-
formed as described previously16. Sendai virus-based reprogramming was carried
out according to themanufacturer’s protocol (CytoTune-iPS ReprogrammingKit,
Life Technologies). Colonies with typical iPS cell morphology were isolated and
manually propagated as described previously26 in Knockout DMEM medium
(Invitrogen) supplemented with 20% knockout serum replacement (Invitrogen),
0.1mM nonessential amino acids (Invitrogen), 1mM L-glutamine (Invitrogen),
0.1mM b-mercaptoethanol (Sigma), 13 penicillin–streptomycin (Invitrogen)
and 4 ngml21 basic fibroblast growth factor (Sigma). All cell cultures were free
of mycoplasma contamination. Origin of all cell lines has been authenticated by
STR and mtDNA genotyping.
Fibroblast differentiation. Differentiation of PSCs to fibroblasts was induced
by culture in fibroblast medium (DMEM F12 with 10% FBS) for 2–3 weeks in
absence of mouse embryonic fibroblast (mEF) feeder layers. Resulting differen-
tiated cells were FACS sorted for TRA-1-602 (BD Biosciences), SSEA42 (Santa
Cruz), CD562 (BD Biosciences) and CD131 (BD Biosciences) cells28. The CD131
cells were further expanded in the fibroblast medium.
NPCdifferentiation and culture.ForNPCdifferentiation, a published protocol14
was followed with minor modifications. PSCs were collected using collagenase IV
(Life Technologies), washed twicewith 13DPBSwithout calciumandmagnesium
(Corning Cellgro), and cultured in Neural Induction Medium 1 (NIM-1: 50%
Advanced DMEM/F12 (Invitrogen), 50% Neurobasal (Invitrogen), 13 B27
(Invitrogen), 13 N2 (Invitrogen), 2mM GlutaMAX (Invitrogen) supplemented
with 10 ngml21 hLIF (Peprotech), 4mM CHIR99021 (Selleckchem), 3mM
SB431542 (Selleckchem), 2mM dorsomorphin (Sigma), and 0.1mM Compound
E (EMD Chemicals Inc.)). Cells were cultured in NIM-1 medium for 2 days with
daily medium change and then switched to Neural Induction Medium 2 (NIM-2:
50% Advanced DMEM/F12, 50%Neurobasal, 13N2, 13 B27, 2mMGlutaMAX
and 10ngml21 hLIF, 4mM CHIR99021, 3mM SB431542 and 0.1mM Compound
E). After 5 days culture in NIM-2 (daily medium change), cells were treated with
10mM Y27632 (Selleckchem) for 1 h and ‘dome’-shaped colonies were manually
picked and treated with Accumax (Innovative Cell Technologies) for 10 min at
37 uC. Cells were then gently pipetted to obtain single cell suspension and replated
onto Matrigel-coated 6-well plates at a density 3.53 104 per cm2 in Neural
Progenitor cell Maintenance Medium (NPMM: 50% Advanced DMEM/F12,
50% Neurobasal, 13 B27, 13 N2, 2mM GlutaMAX, 10 ngml21 hLIF, 3mM
CHIR99021 and 2mM SB431542) supplemented with 10mMY27632. NPCs were
maintained on Matrigel-coated dishes in NPMM with daily medium change and
passaged upon reaching 70% to 80% confluence using Accumax.
Skeletal muscle differentiation. Skeletal muscle differentiation was based on a
previous report with minor modifications17. Briefly, PSCs plated on Matrigel-
coated plates were grown to 40% confluence in mTeSR1 medium and then
switched to Skeletal Muscle Induction Medium (SMIM, DMEM/F12, ITS, 3mM
CHIR99021). After 4 days culture in SMIM with daily medium change, cells were
cultured in Skeletal Muscle Expansion Medium (SMEM: DMEM/F12, ITS and
20ngml21 FGF2) for an additional 14 days with daily medium change. Cells were
then cultured in Skeletal Muscle Differentiation Medium (SMDM: DMEM/F12
and ITS only) for an additional 18 days.
Cardiomyocyte differentiation. Cardiomyocyte differentiation was performed
with adaptation based on the inhibition of GSK3 and Wnt pathways15. Briefly,
PSCs were collected after Accutase (Life Technologies) treatment and cultured
on Matrigel-coated plates in RPMI supplemented with B27 without insulin
(Invitrogen) to 80–90% confluency. Cells were then incubated with 12mM
CHIR99021 (Selleckchem) for 16 h. At day 3, cells were incubated with 5mM
IWP2 (Tocris) for 48 h. At day 7, medium was replaced to RPMI supplemented
with complete B27. Medium was replaced every 3 days. Contracting cardiomyo-
cytes were observed on day 12 of differentiation.
Immunocytochemistry. Cultured cells were fixed with 4% paraformaldehyde for
15 min at room temperature and then permeabilized with 0.2% Triton X-100 in
PBS for 10min. Cells were washed 33with PBST (PBS 13, 0.02%Tween-20) and
blockedwith 10%goat or donkey serum (Sigma) for 1 h at room temperature. Cells
were then incubated with primary antibodies diluted in PBST overnight at 4 uC,
washed 33with PBST and incubatedwith secondary antibodies (1:500,Molecular
Probes) for 1 h at room temperature. Cells were washed 33 and mounted in
Prolong Gold Antifade Mountant (Life Technologies). Image acquisition was
performed on a Zeiss LSM 780 confocal microscope. Primary antibodies were:
PAX6 (1:100, Convance), NESTIN (1:200, Millipore), MF20 (1:100, DSHB),
OCT4 (1:100, Santa Cruz) and NANOG (1:40, R&D Systems).
Teratoma assay. Approximately 3–5 million undifferentiated PSCs were injected
into the hindleg muscle of 8-week-old, SCID, beige male mice (Charles River)
using an 18-gauge needle. Six to seven weeks after injection, mice were euthanized
and tumours were dissected, sectioned and histologically characterized for the
presence of representative tissues as described previously7. The experiments were
not randomized, and the investigators were not blinded to allocation during
experiments and outcome assessment.
mtDNA heteroplasmy analysis by ARMs-qPCR. The amplification refractory
mutation system quantitative PCR assay (ARMs-qPCR) was used to measure
mtDNA carryover in Leigh-NT1 and NT2 as previously described16. Primers
and TaqMan MGB probes were designed to detect the 8993T.G mutation site.
The nondiscriminative (ND) and discriminative (D) assays were mixed and mea-
sured with Rotor-Gene Multiplex PCR Kit (Qiagen). All reactions were run in
duplicate with two different amounts of input DNA: 1–4 ng and 1:8 dilutions. The
SDS software generated a standard curve using four eightfold dilutions plus a final
fourfold dilution. The percentage of mtDNA carryover in relation to the total
mtDNA content was calculated by the equation: heteroplasmy5 1003(quantity
D/quantity ND). ARMs-qPCR was also applied to detect 8993T.G, 3243A.G
and 13513G.A heteroplasmy levels in fibroblasts and iPS cells using primers and
TaqMan MGB probes specifically targeting to mutation sites.
Whole mtDNA sequencing analysis by MiSeq. Single PCR amplification of
entire human mtDNA was performed with primers mtDNA-F-2120, (GGAC
ACTAGGAAAAAACCTTGTAGAGAGAG) and mtDNA-R-2119 (AAAGAGC
TGTTCCTCTTTGGACTAACA) under the following conditions: 94 uC for 1min
followed 98 uC for 10 s and 68 uC for 16min330 cycles and then 72 uC for 10min.
PCR amplifications were performed using TAKARA LA Taq polymerase (Takara
Biotechnology) and the concentrations of PCR products were measured using a
Qubit 2.0 Fluorometer. The Nextera XT DNA sample preparation kit (Illumina)
was used to prepare the libraries. Sequencingwas performed on an IlluminaMiSeq
instrument and the data were analysed using NextGENe software. Briefly,
sequence reads ranging from 100 to 200 bp were quality filtered and processed
using BLAT algorithm. Sequence error correction feature (condensation) was
performed to reduce false-positive variants and produce sample consensus
sequence and variant calls. Alignment without sequence condensation was used
to calculate percentage of mitochondrial genome with depth of coverage of 1,000.
Starting from quality FASTQ reads, the reads were quality filtered and converted
to FASTA format. Filtered reads were then aligned to the revised Cambridge
Reference Sequence (rCRS) of the human mtDNA (NC_012920.1) followed by
variant calling. Variant heteroplasmy was calculated by NextGENe software as
follows: Base heteroplasmy (mutant allele frequency %)5mutant allele (for-
ward1 reverse)/total coverage of all alleles C, G, T, A (forward1 reverse)3 100.
The clinical significance of the variantswas then analysedwithMitoMaster (http://
www.mitomap.org/MITOMASTER/WebHome).
Live cell oxygen consumption. XF24 or XF96 extracellular flux analysers
(Seahorse Biosciences) were used to measure oxygen consumption rates (OCR)
as described12. In brief, stem-cell-derived fibroblasts were seeded at a density of
50,000 cells per well of a XF24 cell culture microplate and incubated for 24 h to
ensure attachment. Before assay, cells were equilibrated for 1 h in unbuffered
XF assay medium supplemented with 25mM glucose, 1mM sodium pyruvate,
2mM glutamax, 13 nonessential amino acids and 1% FBS in a non-CO2 incub-
ator. Mitochondrial processes were examined through sequential injections of
oligomycin (0.5mgml21), carbonyl cyanide 4-(trifluoromethoxy) phenylhydra-
zone (FCCP, 1mM) and rotenone (0.5mM)/antimycin A (1mM). Indices of
mitochondrial function were calculated as basal respiration rate (baseline
OCR 2 rotenone/antimycin A OCR), ATP dependent (basal respiration rate 2
oligomycin OCAR), maximal respiration rate (FCCP OCR2 rotenone/antimycin
A OCR) and oxidative reserve (maximal respiration rate 2 basal respiration
rate). For other cell types, an XF96 extracellular flux analyser was used
with 20,000 cells seeded to each well of a XF96 cell culture microplate. After a
24-h attachment period, mitochondrial processes were examined using the same
protocol as above. Each plotted value was normalized to total protein
quantified using a Bradford protein assay (Bio-rad). Results were presented as
mean 6 s.e.m. One-way ANOVA was used for three group comparisons and
Student’s t-test was used for two group comparisons. A P value less than 0.05
was considered significant.
Flow cytometric analysis.The efficiency of differentiation protocols was assessed
by FACS. For cardiomyocyte differentiation, 0.25 million cells were fixed in the
presence of 1% (vol/vol) paraformaldehyde at room temperature for 20min. Fixed
cells were then incubated in 90% (vol/vol) coldmethanol for 15min at 4 uC, rinsed
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two times and incubated overnight at 4 uC with a primary antibodies against
GATA4 (Santa Cruz) and cTnT (Pierce). After staining, cells were rinsed two
times and incubated in the presence of 1:1,000 secondary antibodies (donkey
Alexa 488 and 567;Molecular Probes) for 30min. After staining, cells werewashed
two times and re-suspended for analysis.
Real time RT–PCR. RNA was isolated using RNeasy kit (Qiagen) as per manu-
facturer’s instructions. cDNAsynthesis was performed using the iScriptTMcDNA
synthesis kit for RT–PCR (BioRad). Real-timePCRwasperformed using the SYBR
Green Supermix (BioRad). The levels of expression of respective genes were nor-
malized to corresponding 18S values and are shown as fold change relative to the
value of the control sample. All reactions were done in triplicate.
RNA-seq library construction and data analysis. RNAwas isolated with Micro-
to-Midi Total RNA Purification System (Life Technologies), quality evaluated
(RNA6000 Nano Kit and BioAnalyzer 2100, Agilent) made into sequencing
libraries, sequenced and mapped as previously described26. Libraries were con-
structed using 500ng input RNA per sample. Approximately 27million reads
were generated per sample, and 73%of these reads were uniquelymapped. Counts
for each genewere quantified using the python script rpkmforgenes and annotated
using Ensembl GRCh37. Genes without at least one sample with at least five reads
were removed from the analysis. The count data was normalized and differential
expression was performed using the R (v.3.1.1) package DESeq2 (v.1.4.5).
Briefly, DESeq2 uses negative binomial generalized linear models and shrinkage
estimation for dispersions and fold changes to improve stability and interpret-
ability of the estimates29. It reports a P value and an adjusted P value using the
Benjamini–Hochberg procedure. Genes with an adjusted P value less than 0.05
were considered differentially expressed unless otherwise noted. Heat maps were
constructed using the R (v.3.1.1) package gplots (v.2.14.2). Each variable was
standardized by subtraction of its mean value and division by its standard devi-
ation across all samples. All functional enrichment analyses were generated
using the Genomic Regions Enrichment of Annotations Tool (v. 2.0.2)30 with
default settings. Hierarchical clustering was performed with the R package
pvclust, with Euclidian distance and average linkage with 10,000 bootstraps.
28. Paull, D. et al. Nuclear genome transfer in human oocytes eliminates
mitochondrial DNA variants. Nature 493, 632–637 (2013).
29. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and
dispersion for RNA-seq data with DESeq2. Genome Biol. 15, (2014).
30. McLean, C. Y. et al. GREAT improves functional interpretation of cis-regulatory
regions. Nature Biotechnol. 28, 495–501 (2010).
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Extended Data Figure 1 | mtDNA genotyping by Sanger sequencing.
a, Chromatographs showing mtDNA genotyping at 3243 position (arrow)
in representative MELAS iPS cells. b, Chromatographs showing mtDNA
genotyping at 8993 position (arrow). c, mtDNA at 13513 position (arrow) in
representative iPS cells derived from Leigh syndrome patients. d, Chromato-
graphs showing either wild-type A or mutant G allele at position 3243 in
representative MELAS fibroblast clones. e, mtDNA genotyping demonstrated
that all Leigh-iPS cell lines and Leigh-fib contain a G mutation allele at
mtDNA position 8993. f, mtDNA genotyping demonstrated that Leigh-fib and
Leigh-iPS1 cell lines contained a C mutant allele at position 4216 and a
G mutant allele at position 8993, while Leigh-NT1 line carried oocyte mtDNA
with a wild-type T allele at both positions.
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Extended Data Figure 2 | Cytogenetic, pluripotency and teratoma analyses.
a, MELAS-iPS1 and MELAS-iPS2 expressing NANOG detected by immuno-
cytochemistry. Scale bars, 200mm.b, Histological analyses of teratoma tumours
produced after injections of MELAS-iPS1 and MELAS-iPS2 cells into SCID
mice. Scale bars, 200 mm. c, Cytogenetic G-banding analysis confirmed that
Leigh-NT1 and Leigh-iPS1 exhibited normal 46XY karyotypes and Leigh-NT2
exhibited a XXXY tetraploid karyotype. d, Leigh-NT1 and Leigh-iPS1cells
expressed OCT4 and NANOG. Scale bars, 200 mm. e, Histological analyses of
teratoma tumours produced after injections of Leigh-NT1 and Leigh-iPS1
cells into SCID mice. Scale bars, 200 mm. Haematoxylin and eosin staining of
teratoma sections identify derivatives of ectoderm, mesoderm and endoderm.
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Extended Data Figure 3 | Metabolic function in differentiated cells from
MELAS iPS cells. a, OCR/ECAR ratio in MELAS-iPS cells. Mutant MELAS-
iPS1 and MELAS-iPS3 displayed significantly decreased OCR/ECAR ratios
compared towild-typeMELAS-iPS2 (P, 0.05), indicating a greater reliance on
glycolysis (n5 9 per cell line, biological replicates). b, OCR/ECAR ratio in
MELAS-iPS cell derived fibroblasts (n5 10 per cell line, biological replicates).
c, Immunofluorescence analysis for neural progenitor markers in MELAS-iPS
derived NPCs. Scale bar, 100 mm. d, Quantitative analysis of PSC (OCT4
and NANOG) or NPC (SOX1, NESTIN and PAX6) marker expression in
MELAS-iPS cells andNPCs (n5 3 per cell line, biological replicates). e, OCR of
MELAS-iPS cell derived NPCs (n5 6 per cell line, biological replicates). Error
bars are mean6 s.e.m. Significance established with one-way ANOVA with
Tukey’s multiple comparison test.
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Extended Data Figure 4 | Metabolic function in differentiated cells from
Leigh syndrome PSCs. a, OCR/ECAR ratio in Leigh-iPS1, Leigh-iPS2 and
Leigh-NT1 derived fibroblasts, parental and oocyte donor fibroblasts (n5 9, 8,
10, 9 and 8 per cell line, respectively, biological replicates). b, Immunofluo-
rescence analysis of Leigh-iPS1- and Leigh-NT1-derived skeletal muscle cells
labelled with MF20 and myogenin antibodies. Scale bar, 100 mm.
c, Cardiomyocyte differentiation efficiency in Leigh-iPS1 and Leigh-NT1
evaluated by FACS for CTnT-Alexa 647 and GATA4-FITC antibodies
(n5 3 per cell line, biological replicates). Error bars are mean6 s.e.m.
Significance established with one-way ANOVA with Tukey’s multiple
comparison test.
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Extended Data Figure 5 | Metabolic function in hESO-NT1 and hESO-8.
a, Immunofluorescence analysis of hESO-NT1 and hESO-8 derivedNPCs with
nestin and PAX6 antibodies. Scale bar, 100 mm. b, Metabolic profiles of NPCs
differentiated from hESO-NT1 and hESO-8 (n5 6 per cell line, biological
replicates). c, Immunofluorescence analysis of hESO-NT1 and hESO-8 derived
cardiomyocytes with troponin I and NKX2.5 antibodies. Scale bar, 100 mm.
d, Efficiency of cardiomyocyte differentiation in hESO-NT1 and hESO-8
evaluated by FACS analysis for CTnT-Alexa 647 and GATA4-FITC antibodies
(n5 3 per cell line, biological replicates). e, OCR of hESO-NT1 and hESO-8
derived cardiomyocytes (n5 6 per cell line, biological replicates). Error bars
are mean 6 s.e.m. Significance established with Student’s t-test.
LETTER RESEARCH
G2015 Macmillan Publishers Limited. All rights reserved
RESEARCH LETTER
G2015 Macmillan Publishers Limited. All rights reserved
Extended Data Figure 6 | RNA-seq analyses of fibroblasts differentiated
from MELAS and Leigh syndrome PSCs carrying wild-type and mutant
mtDNA. a, Heat map showing all differentially expressed 1,118 genes
(adjusted P value, 0.05) between fibroblasts differentiated from mutant
MELAS iPS cells (n5 4 from biological duplicates of MELAS-iPS2 and
MELAS-iPS4) andwild-typeMELAS iPS cells (n5 4 frombiological duplicates
of MELAS-iPS1 and MELAS-iPS3). b, Heat map demonstrating differentially
expressed 2,950 genes (adjusted P value, 0.05) between fibroblasts derived
from wild-type Leigh-NT1 (biological duplicates) and mutant Leigh iPS cells
(n5 6 from biological duplicates of Leigh-iPS1, Leigh-iPS2 and Leigh-iPS3).
c, Hierarchical clustering using Euclidean distance and average linkage using
pvclust, which employs a multiple bootstrap resampling algorithm to
calculate the approximately unbiased (AU, red) and bootstrap probability
(BU, green) values for cluster distinctions. Hierarchical clustering showed that
the Leigh-NT1 fibroblasts were similar to hESO-NT1, hESO-NT2, hESO-7 and
hESO-8 fibroblasts. d, Mean log2 normalized counts6 s.e.m. for genes
previously reported to be differentially expressed inMELAScytoplasmic hybrid
clones and involved in metabolic and stress response, signalling pathways
and epigenetic modifying processes (wild type fibroblast; n5 14 from
biological duplicates of 7 independent cell lines; mutant fibroblast n5 10 from
biological duplicates of 5 independent cell lines).
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Extended Data Figure 7 | RNA-seq analysis of the mitochondrial
transcriptome. Circular heat map displaying average expression levels for all
mitochondrial genes grouped by sample differentiation status and presence or
absence of a mutation in the mitochondrial genome (Fib mutant (including
primary fibroblasts and PSC derived fibroblasts) with mutant mtDNA n5 14,
biological duplicates of 7 independent cell lines; Fib wild type (including
primary fibroblasts and PSC derived fibroblasts) with wild-type mtDNA
n5 14, biological duplicates of 7 independent cell lines; PSC mutant
(undifferentiated IVF-ESC, NT-ESC and iPS cells) with mutantmtDNA n5 3;
PSC wild type (undifferentiated IVF-ESC, NT-ESC and iPS cells) with wild-
type mtDNA n5 12). The expression of mtDNA-encoded genes was similar
irrespective of 3243A.G or 8993T.G mutations (adjusted P value .0.05).
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Extended Data Table 1 | Mutation loads in Leigh syndrome iPS cells with homoplasmic mutations
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Extended Data Table 2 | Quantitative mutant mtDNA carryover analysis in Leigh-NT1
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Extended Data Table 3 | Short tandem repeat analysis of oocyte donors, Leigh-NT2 and iPS cells from the Leigh syndrome patient
*Male samples only show one mark of DXS2506 on the X chromosome.
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